Semin Thromb Hemost 2021; 47(05): 581-588
DOI: 10.1055/s-0040-1715795
Review Article

Hyperfibrinolysis in Patients with Solid Malignant Neoplasms: A Systematic Review

Anne Winther-Larsen
1   Thrombosis and Hemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
2   Department of Clinical Biochemistry, Viborg Regional Hospital, Viborg, Denmark
,
Birgitte Sandfeld-Paulsen
1   Thrombosis and Hemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
,
Anne-Mette Hvas
1   Thrombosis and Hemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
› Author Affiliations

Abstract

Solid malignant neoplasms have the capability of disturbing the fibrinolytic system, leading to primary hyperfibrinolysis, a paraneoplastic syndrome that potentially results in severe bleeding. Yet, the full extent of primary hyperfibrinolysis in solid malignant neoplasms is unknown. Thus, the purpose of this study was to systematically review the current literature regarding clinical manifestations, biochemical diagnosis, and treatment of primary hyperfibrinolysis in patients with solid malignant neoplasms. The review was performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The databases PubMed, Embase, Scopus, and Web of Science were searched on December 5, 2019, without time limits. Studies were included if they comprised at least one biochemical marker of fibrinolysis in addition to fibrinogen degradation products such as D-dimer, and furthermore included a correlation between biochemical marker and clinical outcome. In total, 12 studies were included. All studies were case reports including a total of 21 patients. Prostate cancer was the most frequently represented cancer type (76%), and the majority of cancer patients had metastatic disease (81%). Spontaneous bleeding was the clinical presentation in the majority of patients (76%), and the most frequently localization for the bleedings was subcutaneous. Antifibrinolytic agents were the most commonly used treatment and ceased bleedings in 80% of patients. Three patients died of uncontrolled bleedings. In conclusion, primary hyperfibrinolysis induced by solid malignant neoplasms is a rare but potentially life-threatening condition that should be considered, especially in patients with metastatic disease presenting with serious, spontaneous subcutaneous bleedings. A standardized diagnostic strategy is strongly needed.



Publication History

Article published online:
23 September 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol 2018; 72 (02) 89-93
  • 2 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87 (04) 575-579
  • 3 Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18 (04) 353-372
  • 4 Plantureux L, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel) 2018; 10 (11) 441
  • 5 Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood 2015; 126 (05) 582-588
  • 6 Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol 2017; 118: 79-83
  • 7 Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol 2016; 175 (01) 12-23
  • 8 Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost 2019; 45 (04) 413-422
  • 9 Levi M. Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res 2018; 164 (Suppl. 01) S77-S81
  • 10 Tagnon HJ, Whitmore Jr WF, Shulman NR. Fibrinolysis in metastatic cancer of the prostate. Cancer 1952; 5 (01) 9-12
  • 11 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6 (07) e1000100
  • 12 Rosswick RP. Testosterone-induced activation of fibrinolysis in carcinoma of the prostate. Br J Urol 1967; 39 (02) 143-146
  • 13 Pellman CM, Ridlon HC, Phillips LL. Manifestation and management of hypofibrinogenemia and fibrinolysis in patients with carcinoma of the prostate. J Urol 1966; 96 (03) 375-379
  • 14 Stern NS, Catone GA. Primary fibrinolysis after oral surgery. J Oral Surg 1975; 33 (01) 49-52
  • 15 Okajima K, Kohno I, Tsuruta J, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res 1992; 66 (06) 717-727
  • 16 Sallah S, Gagnon GA. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 2000; 18 (03) 191-196
  • 17 Kulić A, Cvetković Z, Libek V. Primary hyperfibrinolysis as the presenting sign of prostate cancer: a case report. Vojnosanit Pregl 2016; 73 (09) 877-880
  • 18 Cvetkovic Z, Cvetkovic B, Cvetkovic D, Libek V, Perunicic-Pekovic G. Paraneoplastic bleeding disorder due to isolated hypofibrinogenemia: a case report. Hippokratia 2009; 13 (01) 52-54
  • 19 Jafri MAS, Cohen JV, Much MA, Petrylak DP, Podoltsev NA. A patient with pancytopenia, intractable epistaxis, and metastatic prostate cancer: how correct diagnosis of primary hyperfibrinolysis helps to stop the bleeding. Clin Genitourin Cancer 2016; 14 (05) e545-e548
  • 20 Bennett B, Croll AM, Robbie LA, Herriot R. Tumour cell u-PA as a cause of fibrinolytic bleeding in metastatic disease. Br J Haematol 1997; 99 (03) 570-574
  • 21 Naina HVK, Patnaik MM, Ali UA, Chen D, Ashrani AA. Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol 2010; 28 (11) e167-e168
  • 22 Blaise S, Rumeau-Trividic M, Le Brun V, Bedane C, Bonnetblanc JM. Melanoma associated with subacute primitive fibrinolysis. J Eur Acad Dermatol Venereol 2005; 19 (06) 737-739
  • 23 Meijer K, Smid WM, Geerards S, van der Meer J. Hyperfibrinogenolysis in disseminated adenocarcinoma. Blood Coagul Fibrinolysis 1998; 9 (03) 279-283
  • 24 Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10 (01) 39-49
  • 25 Shariat SF, Roehrborn CG, McConnell JD. et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25 (04) 349-355
  • 26 Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 2003; 61 (05) 1053-1058
  • 27 Grebenchtchikov N, Maguire TM, Riisbro R. et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep 2005; 14 (01) 235-239
  • 28 Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 2014; 16 (04) 428
  • 29 Hyman DM, Soff GA, Kampel LJ. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology 2011; 81 (02) 119-125
  • 30 Gando S, Levi M, Toh C-H. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2 (01) 16037